|
rheumatoid arthritis
|
MONDO_0008383 |
[A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.] |
|
autoimmune disease
|
DOID_417 |
[An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.] |
|
Monitoring
|
NCIT_C61256 |
[The act of observing something (and sometimes keeping a record of it).] |
|
process
|
BFO_0000015 |
[p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])] |
|
cancer marker
|
OPMI_0000464 |
|
|
disease biomarker
|
OPMI_0000450 |
[A biomarker that is indicative of a disease] |
|
celiac disease
|
DOID_10608 |
[An autoimmune disease of gastrointestinal tract that is caused by a reaction located_in small intestine to gliadin, a prolamin (gluten protein) found in wheat, and similar proteins found in the crops of the tribe Triticeae. The disease is associated with HLA-DQ gene. It has_symptom abdominal pain, has_symptom constipation, has_symptom diarrhea, has_symptom nausea and vomiting, and has_symptom loss of appetite.] |
|
Pharmacodynamic Biomarker
|
NCIT_C201365 |
[A response biomarker that indicates biologic activity of a medical product or environmental agent without necessarily drawing conclusions about efficacy or disease outcome or necessarily linking this activity to an established mechanism of action. (NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource)] |
|
Response Biomarker
|
NCIT_C201303 |
[A biomarker used to show that a biological response, potentially beneficial or harmful, has occurred in an individual who has been exposed to a medical product or an environmental agent. (NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource)] |
|
saliva
|
UBERON_0001836 |
[A fluid produced in the oral cavity by salivary glands, typically used in predigestion, but also in other functions.] |
|
organism substance
|
UBERON_0000463 |
[Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body.] |
|
proteinuria
|
DOID_576 |
[A kidney disease that is characterized by the presence of excess proteins in the urine.] |
|
kidney disease
|
DOID_557 |
[A urinary system disease that is located_in the kidney.] |
|
Monitoring Biomarker
|
NCIT_C201362 |
[A biomarker measured repeatedly for assessing status of a disease or medical condition or for evidence of exposure to (or effect of) a medical product or an environmental agent. (NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource)] |
|
biomarker
|
OPMI_0000445 |
[A material entity that has a measurable quality or process profile(s), which can be used as an indicator of an underlying biological state or identity.] |
|
biological feature
|
MI_0252 |
[Property of a subsequence that may be involved with or interfere with the binding of a molecule and are supported by experimental evidences.] |
|
quality
|
BFO_0000019 |
|
|
metabolic syndrome
|
EFO_0000195 |
[A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)] |
|
disease of metabolism
|
DOID_0014667 |
[A disease that involving errors in metabolic processes of building or degradation of molecules.] |
|
malignant
|
EFO_0006851 |
[Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host] |